DuChemBio
DuChemBio is Korea's No.1 PET radiopharmaceutical company, manufacturing and licensing nine diagnostic agents for neurology and oncology across a 12-center GMP-certified network serving hospitals and global pharma partners.
- Company typePublic
- Founded2002
- HeadquartersSeoul, South Korea
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What DuChemBio does
DuChemBio Co., Ltd. (듀켐바이오) is a Seoul-headquartered, KOSDAQ-listed (ticker 176750) radiopharmaceutical company founded in 2002 and Korea's No.1 PET radiopharmaceutical manufacturer by market share across all product categories. The company develops, manufactures, and commercializes a portfolio of nine diagnostic PET radiopharmaceuticals spanning neurology (FP-CIT for Parkinson's, F-DOPA/Dopaceq, Neuraceq and VIZAMYL for Alzheimer's) and oncology (PROSTASEEK and FACBC for prostate cancer, FES for breast cancer, FDG for general tumor imaging, NaF for bone imaging), supported by proprietary manufacturing technology including the world's first F-DOPA neutralization process, 68Ga high-radioactivity generator production, and cassette-based manufacturing know-how. DuChemBio also produces the PARTIO VS automated dual-vial PET distribution equipment and operates a CDMO/contract manufacturing business for global radiopharmaceutical developers including Cerveau Technologies and Life Molecular Imaging.
The company's revenue model combines direct B2B sales of radiopharmaceutical products to Korean hospital nuclear medicine departments — supplied through 12 manufacturing centers (6 GMP-certified, multiple valid through 2027-2028) co-located with major university hospitals — with international technology licensing and royalty streams (Cyclotek for Australia/NZ and six Southeast Asian markets, PETPharm Biotech for Taiwan, Nihon Medi-Physics for FACBC in Korea, Life Molecular Imaging for Neuraceq). 2024 revenue was 35,601 million KRW (~$26.7M) with operating income of 5,076M KRW and net income of 7,994M KRW; Q3 2025 revenue of 27,889M KRW indicates material year-over-year acceleration. Following the August 2021 absorption of Carecamp Inc.'s radiopharmaceutical business, DuChemBio operates as part of the GeoYoung Group conglomerate, with CEO Kim Sang-Woo (김상우) leading a 51-100 employee organization. The December 2024 KOSDAQ IPO and July 2025 MFDS approval of PROSTASEEK — Korea's first domestically approved prostate cancer diagnostic PET agent — frame the current strategic agenda: scale the oncology franchise, extend the Asia-Pacific licensing footprint, and pursue theranostic adjacencies.
DuChemBio firmographics
Firmographics- Name
- DuChemBio
- Legal name
- DuChemBio Co., Ltd.
- Website
- https://duchembio.com
- Company type
- Public
- Founded year
- 2002
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- DuChemBio is Korea's No.1 PET radiopharmaceutical company, manufacturing and licensing nine diagnostic agents for neurology and oncology across a 12-center GMP-certified network serving hospitals and global pharma partners.
- Ownership category
- akta.pro rank
DuChemBio industry classification
Industry- Product category
- Radiopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish) (HLAIAGAF)
- akta.pro secondary industries
- Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA), Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC) (EUAKAIAC), Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE)
Keywords
Where DuChemBio is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Offices9 records
Markets served
DuChemBio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Radiopharmaceutical Product Sales: Direct sales of diagnostic radiopharmaceuticals (FDG, FP-CIT, F-DOPA, Neuraceq, Vizamyl, PROSTASEEK, FACBC, FES, NaF) to hospitals and medical institutions across Korea through 12 manufacturing centers
- CDMO/Contract Manufacturing Services: Manufacturing services for third-party pharmaceutical companies including Cerveau Technologies (MK-6240 Tau Tracer) and Life Molecular Imaging (PI-2620 Tau Tracer); expansion into radiopharmaceutical CDMO market
- Technology Licensing and Export: Licensing out of proprietary technologies and manufacturing know-how to international partners including FP-CIT licensing to Cyclotek for Australia/NZ/SE Asia, F-DOPA/FES cassette technology exports, and manufacturing technology transfers
Go-to-market motion2 records
Distribution channels5 records
Marketing channels4 records
DuChemBio product offering
Product offeringCore offering
DuChemBio develops, manufactures, and commercializes PET diagnostic radiopharmaceuticals used in hospital nuclear medicine departments for cancer diagnosis (prostate, breast, general tumors), neurological disease diagnosis (Parkinson's, Alzheimer's), and bone imaging. The company operates a portfolio of nine radiopharmaceutical products and an automated distribution system, supplying hospitals directly across Korea through 12 manufacturing centers and licensing its technologies and products to international partners across Asia-Pacific and beyond.
Product overview
DuChemBio is Korea's leading radiopharmaceutical company offering a comprehensive portfolio of diagnostic radiopharmaceuticals and related equipment. The core portfolio consists of nine PET radiopharmaceutical products spanning neurology (FP-CIT for Parkinson's, F-DOPA/Dopaceq for brain tumors and Parkinson's, Neuraceq and VIZAMYL for Alzheimer's), oncology (PROSTASEEK™ for prostate cancer, FACBC for prostate cancer, FES for breast cancer, FDG for general tumor imaging), and bone diagnostics (NaF). The company also manufactures the PARTIO VS distribution equipment. These products work together to enable molecular imaging diagnostics across cancer, neurological disorders, and bone diseases, with the company leveraging its 12 manufacturing facilities nationwide to supply hospitals and clinics throughout Korea.
Differentiator
Problem solved
Functional benefit
Brands
- PROSTASEEK™: Prostate cancer diagnostic radiopharmaceutical (18F-flotufolastat) - Korea's first MFDS-approved prostate cancer diagnostic agent with U.S. FDA approval
- Memocare™
- Dopaceq (도파체크)
- Neuraceq (뉴라체크)
- VIZAMYL
Products and services
- FP-CIT (에프피시티아이티) PET radiopharmaceutical that measures dopamine transporter density in the brain striatum to diagnose Parkinson's disease and Parkinsonian syndrome. The world's first brain imaging tracer for Parkinson's disease diagnosis. DuChemBio owns all global FP-CIT technology and clinical data rights outside Korea.
- F-DOPA (도파체크, Dopaceq) PET radiopharmaceutical for brain tumor diagnosis and Parkinson's disease assessment using the world's first applied neutralization technology. Measures functional loss of dopamine nerve terminals in the substantia nigra. Also covers tumors not diagnosable with conventional FDG, including neuroendocrine tumors and pheochromocytoma.
- Neuraceq (뉴라체크) First radiopharmaceutical in Asia for beta-amyloid imaging in Alzheimer's disease diagnosis. Measures beta-amyloid distribution and density in the brain, essential for differentiating Alzheimer's from vascular dementia. Licensed from Life Molecular Imaging for Korean commercialization.
- VIZAMYL (비자밀) PET imaging agent for early Alzheimer's diagnosis that confirms beta-amyloid neuritic plaque density. The only amyloid imaging agent with FDA approval enabling color image interpretation, providing consistency and clinical diagnostic certainty.
- PROSTASEEK (프로스타시크주, Flotufolastat 18F) FDA-approved PSMA-targeted PET radiopharmaceutical for prostate cancer imaging. Detects PSMA-positive lesions in men with suspected recurrence or metastatic disease. The F-18 isotope provides higher image resolution and sensitivity compared to Ga-68 PSMA products, with a half-life of approximately 110 minutes. Korea's first MFDS-approved prostate cancer diagnostic agent.
- FES (플루오로에스트라디올 18F) World's first radiopharmaceutical for breast cancer diagnosis. Used for metastatic and recurrent breast cancer diagnosis and determination of estrogen receptor (ER) status to assess treatment appropriateness.
- FACBC (플루시클로빈) Korea's first PET diagnostic agent for recurrent prostate cancer using 18F-fluciclovine. Diagnostic imaging agent for recurrent or metastatic prostate cancer with NDA approval obtained September 2021.
- FDG (에프디지) Fundamental tumor diagnostic radiopharmaceutical using glucose metabolism principle to diagnose all tumors that metabolize glucose faster than normal cells. The foundational product category in radiopharmaceutical industry.
- NaF (메타스캔) Bone diagnostic radiopharmaceutical for imaging altered osteogenic active areas. Used for identifying changes in bone formation activity.
- PARTIO VS Dual-vial automated distribution system for PET radiopharmaceuticals. Transfers vial-formatted PET radiopharmaceuticals to syringe format with zero consumable costs. Features include dual-vial individual distribution, dose calibrator QC, timer setting, automatic radiation calculation based on patient weight, and re-calibration distribution capability.
Quantifiable outcome
- No. 1 market share in all PET radiopharmaceutical product categories in Korea (2024)
- +2 more outcomes
Companies that use DuChemBio
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
DuChemBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
DuChemBio partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered major, core and minor.
- Korean Society of NeurologymajorMOU for early diagnosis cooperation in Alzheimer's and other neurological diseases.
- NeuroFitmajorJoint development of Parkinson's and Alzheimer's disease diagnostic platform combining DuChemBio's radiopharmaceuticals with NeuroFit's technology.
- CyclotekcoreExclusive licensing agreement expanded from Australia/New Zealand to 6 additional Southeast Asian countries (India, Singapore, Malaysia, Thailand, Indonesia, Vietnam) for manufacturing and commercialization of Parkinson's disease diagnostic PET tracer 18F-FP-CIT. Cyclotek leads regulatory filings and builds local manufacturing capacity.
- PETPharm BiotechcoreExclusive technology transfer (L/O) agreement for Parkinson's disease diagnostic agent 18F-FP-CIT in Taiwan market.
- Life Molecular Imaging (LMI)coreClinical and technology transfer supply agreement for PI-2620 Tau PET Tracer for Alzheimer's disease and Progressive Supranuclear Palsy (PSP) diagnosis.
- Cerveau TechnologiescoreManufacturing services agreement for MK-6240 Tau PET Tracer, a dementia diagnostic agent for Alzheimer's disease.
- Uzbekistan GovernmentminorMOU for establishment and operation of radiopharmaceutical manufacturing facility in Uzbekistan.
- Telix PharmaceuticalsminorExclusive distribution agreement for prostate cancer radiopharmaceutical in Australia.
- Isotope Technologies Munich (ITM)majorExclusive licensing and development agreement for Solucin (neuroendocrine tumor therapeutic agent) with clinical trials in Korea.
- Nihon Medi-Physics (NMP)coreExclusive licensing agreement for domestic development and commercialization of FACBC (prostate cancer diagnostic agent) in Korea.
- Asan Medical CentercoreFES licensing agreement and FP-CIT patent acquisition for overseas export.
- Korea Atomic Energy Research Institute (KAERI)majorTechnology licensing agreement for manufacturing technology of bombesin diagnostic and therapeutic agents for prostate cancer.
- CerecinminorDomestic licensing agreement for cognitive function improvement medical food.
- Life Molecular Imaging (LMI)coreExclusive licensing agreement for domestic development and commercialization of Neuraceq (Alzheimer's diagnostic agent) in Korea.
Scale indicators8 records
Recent moves10 records
Expansion highlights6 records
DuChemBio competitors and assessment
Company assessmentDirect peers
- Curium: Curium is one of the world's largest radiopharmaceutical manufacturers, producing SPECT/PET tracers including FDG and PSMA products across a global GMP manufacturing network. Closely matches DuChemBio's business model of multi-center GMP production and direct hospital supply.
- Life Molecular Imaging: LMI developed Neuraceq (florbetaben) for Alzheimer's beta-amyloid imaging, which DuChemBio licenses and distributes in Korea. Both companies also work on next-generation tau tracers (PI-2620) where DuChemBio performs CDMO manufacturing, making them peers across both product and CDMO dimensions.
- Cerveau Technologies: Cerveau develops MK-6240, a leading F-18 tau PET tracer for Alzheimer's disease, and uses DuChemBio as its CDMO manufacturing partner in Asia. Operates in the same tau imaging space as DuChemBio's pipeline and shares the same hospital nuclear medicine customer base.
- Telix Pharmaceuticals: Telix markets Illuccix (Ga-68 PSMA-11) and is developing F-18 PSMA tracers for prostate cancer imaging, directly overlapping with DuChemBio's PROSTASEEK (flotufolastat) franchise and competing for the same hospital nuclear medicine customers. Telix is also already a DuChemBio distribution partner in Australia.
- Lantheus Holdings: Lantheus is the leading U.S. diagnostic radiopharmaceutical company with PYLARIFY (F-18 piflufolastat), the most direct global competitor to PROSTASEEK in PSMA-PET. It also sells other oncology and neurology tracers, mirroring DuChemBio's portfolio breadth.
- Isotope Technologies Munich (ITM): ITM develops therapeutic radiopharmaceuticals including Solucin (which DuChemBio is licensing and clinically developing in Korea). Specializes in radioisotope production and targeted radionuclide therapy, directly overlapping with DuChemBio's emerging therapeutic ambitions and pipeline direction.
Broad incumbents
- GE HealthCare: GE HealthCare operates a large radiopharma segment (formerly GE Healthcare Pharmaceutical Diagnostics) producing PET/SPECT tracers such as Vizamyl (already in-licensed by DuChemBio for Korea) and competes broadly in molecular imaging. A larger, diversified incumbent with overlapping but not specialty-focused product set.
- Bayer (Radiology): Bayer markets Xofigo (Ra-223) and historically operated a broader radiopharma/contrast portfolio; a diversified pharma incumbent with relevant but non-specialty nuclear medicine assets. Useful as a benchmark for global distribution reach DuChemBio aspires to via partnerships.
- Bracco Imaging: Bracco is a global diagnostic imaging company with a radiopharmaceutical portfolio and significant contrast media business. Comparable in product category breadth but more diversified across imaging modalities than DuChemBio's pure-play radiopharma focus.
Regional players
- Nihon Medi-Physics: Japan's largest radiopharmaceutical manufacturer, a GE HealthCare joint venture that supplies Japanese hospitals with SPECT/PET tracers. DuChemBio licenses FACBC from NMP for Korean distribution; both target the same Asian nuclear medicine market with similar product categories but on opposite sides of the regional divide.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
DuChemBio social profiles
Digital presenceDuChemBio compliance and trust
Trust signalCompliance7 records
DuChemBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
DuChemBio leadership team
Management profileNumber of profiles
Profiles7 records
DuChemBio subsidiaries and ownership
Company hierarchySubsidiaries2 records
DuChemBio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DuChemBio M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DuChemBio
What does DuChemBio do?
DuChemBio develops, manufactures, and commercializes PET diagnostic radiopharmaceuticals used in hospital nuclear medicine departments for cancer diagnosis (prostate, breast, general tumors), neurological disease diagnosis (Parkinson's, Alzheimer's), and bone imaging. The company operates a portfolio of nine radiopharmaceutical products and an automated distribution system, supplying hospitals directly across Korea through 12 manufacturing centers and licensing its technologies and products to international partners across Asia-Pacific and beyond.
Is DuChemBio a public or private company?
DuChemBio is a public company. It is classified as public and is currently operating.
When was DuChemBio founded?
DuChemBio was founded in 2002. It employs 51 to 100 people.
Where is DuChemBio based?
DuChemBio is headquartered in Seoul, South Korea, in the Asia region.
How does DuChemBio make money?
Three revenue lines are on record. Radiopharmaceutical Product Sales are the primary driver. The others are CDMO/Contract Manufacturing Services and technology Licensing and Export.
Who are DuChemBio's main competitors?
Direct peers on record are Curium, Life Molecular Imaging, Cerveau Technologies, Telix Pharmaceuticals, Lantheus Holdings and Isotope Technologies Munich (ITM). Broad incumbents are GE HealthCare, Bayer (Radiology) and Bracco Imaging. Nihon Medi-Physics is listed as a regional player.
Does DuChemBio have an API?
No public API is recorded for DuChemBio.
What industry is DuChemBio in?
DuChemBio's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of HLAIAGAA, Diagnostic Radiopharmaceuticals (SPECT/PET Tracers). Its NAICS code is 325412 and its SIC code is 2834.